Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hain Celestial Group Inc HAIN

The Hain Celestial Group, Inc. is a health and wellness company. The Company is focused on delivering nutrition and well-being. The Company's products across snacks, baby/kids, beverages, meal preparation, and personal care, are marketed and sold in over 70 countries around the world. Its segments include North America and International. The North America segment includes United States and Canada. The International segment includes United Kingdom and Western Europe. Its brands include Garden Veggie Snacks, Terra chips, Garden of Eatin' snacks, Hartley’s Jelly, Earth's Best and Ella's Kitchen baby and kids foods, Celestial Seasonings teas, Joya and Natumi plant-based beverages, Cully & Sully, Yorkshire Provender, New Covent Garden and Imagine soups, Yves and Linda McCartney's (under license) meat-free, and Avalon Organics personal care, among others. Its customer base consists of specialty and natural food distributors, supermarkets and natural food stores, mass-market, and club stores.


NDAQ:HAIN - Post by User

Bullboard Posts
Post by investorblingon Feb 02, 2007 9:53am
300 Views
Post# 12147767

Recommendations for February 2, 2007 (Part 2)

Recommendations for February 2, 2007 (Part 2)

Concorde

Avid Technology | Steven B. Frankel, CFA, AVID : NNM : US$37.09 | US$1, 547.9M | Buy, Target US$47.00

Q1/07 should be the bottom

Badger Meter | John Quealy, BMI : AMEX : US$29.45 | US$409.4M | Buy, Target US$30.00

Q4/06 preview

Cerner Corporation | Dushan Batrovic, CERN : NNM : US$45.80 | US$$3,767.3M | Buy, Target US$55.00

Strong quarter and outlook

Digene | Matthew Scalo, DIGE : NNM : US$52.99 | US$1,236.0M | Buy, Target US$57.00

Good Q; additional DTC spend should benefit F2008

Dolby Laboratories | Steven B. Frankel, CFA, DLB : NYSE : US$33.35 | US$3,761.9M | Buy, Target US$38.00

Making beautiful music: Dolby beats and raises, again!

ESCO Technologies | John Quealy, ESE : NYSE : US$48.70 | US$1,285.7M | Buy, Target US$50.00

Q1/07 preview

Green Mountain Coffee | Scott Van Winkle, CFA, GMCR : NNM : US$64.92 | US$524.3M | Buy, Target US$76.00

Strong results even before Keurig accretion begins

Hain Celestial Group | Scott Van Winkle, CFA, HAIN : NNM : US$29.76 | US$1,226.2M | Buy, Target US$34.00

Weathered the weather well

Mentor Graphics | Dennis C. Wassung, Jr., CFA, MENT : NNM : US$18.68 | US$1,624.7M | Buy, Target US$23.00

Stellar Q4; room for F2008 upside

Nautilus | Stephen Colbert, NLS : NYSE : US$16.41 | US$528.1M | Buy, Target US$17.00

NLS announces intention to purchase Chinese maunfacturing facility

NewWest Gold Corp. | Wendell Zerb, NWG : TSX : C$1.80 | C$105.1M | Speculative Buy, Target C$3.00

Solid Nevada-based exploration portfolio

Occam Networks | Joanna Makris, OCNW : NNM : US$17.60 | US$337.6M | Buy, Target US$22.00

What slowdown? All systems go

Open Text Corporation | Peter Misek, OTEX : NNM : US$18.96 | US$952.2M | OTC : TSX | Hold, Target US$20.00

Preview Q2/F07

QuestAir Technologies | Mark Thompson, CFA, QAR : TSX : C$1.43 | C$74.9M | QAR : LSE | Buy, Target C$1.95

Q1/07 Preview

Rackable Systems | Mark Kelleher, RACK : NNM : US$20.34 | US$583M | Sell , Target US$14

Competition racks guidance; downgrade to SELL

Vertex Pharmaceuticals | Joseph Pantginis, Ph.D., VRTX : NNM : US$34.80 | US$4,311.7M | Buy, Target US$47.00

Runnin' on all pistons

Bullboard Posts